Search companies

Live

GENETIC SIGNATURES LIMITED (ASX: GSS)

Health care · News and insights

Price unavailable

Latest GSS announcements

Announcement Insights

Genetic Signatures Merger Terms Remain Unsettled as AGM Is Delayed

Genetic Signatures’ proposed merger with Microba has remained contested, with shareholders rejecting three resolutions at the 28 October EGM and BCAL Diagnostics opposing the proposed terms. On 12 November, the company delayed its AGM to continue negotiating commercial terms; on 16 November it requested a trading halt ahead of an update on proposed material changes to the merger terms.

Updated 16 Nov 2026, 09:34 AM Sydney time
Share
SourcesTrading HaltPostponement of AGM & Further Addendum to the Notice of AGM3X Initial Directors Interest NoticeNotification regarding unquoted securities - GSSResults of 2026 EGM and Appointment of DirectorBDX: BCAL Welcomes Dr John Melki's Appointment to GSS Board
Comments

Genetic Signatures Halted Ahead Of Proposed Merger Terms Update

2026-11-16 · Health care

GSS: $0.072 +0.00% · MC: $16M

Genetic Signatures requested a trading halt pending an announcement about proposed material changes to the terms of its proposed merger with Microba Life Sciences. The halt is expected to last until the announcement or the start of trading on Wednesday, whichever comes first.

Updated 2026-11-16 09:26
Share
SourcesTrading Halt
Comments

Genetic Signatures Delays AGM As Merger Talks Continue, Withdraws Director Vote

2026-11-12 · Health care

GSS: $0.072 +0.00% · MC: $16M

Genetic Signatures has postponed its AGM to allow more time to negotiate and finalise commercial terms of its proposed merger with Microba Life Sciences. The company has withdrawn the resolution for Dr Jenny Harry’s re-election; she will remain a director, while Anne Lockwood will stand for re-election.

Updated 2026-11-12 19:27
Share
SourcesPostponement of AGM & Further Addendum to the Notice of AGM
Comments

Genetic Signatures Issues Incentive Rights As New Director Discloses Shareholding

2026-11-02 · Health care

GSS: $0.078 +0.00% · MC: $16M

Genetic Signatures issued long-term incentive rights under its employee plan, including rights to key management personnel, and newly appointed director John Robert Melki disclosed an indirect interest in shares held through HSBC Custody Nominees. The company’s 28 October meeting approved Melki’s appointment, while three other resolutions were rejected.

Updated 2026-11-02 14:42
Share
Sources3X Initial Directors Interest NoticeNotification regarding unquoted securities - GSS
Comments

Genetic Signatures shareholders appoint John Melki, reject three other EGM resolutions

2026-10-28 · Health care

GSS: $0.079 +5.33% · MC: $16M

Genetic Signatures shareholders appointed John Melki as a non-executive director at an extraordinary meeting, while rejecting three other resolutions. BCAL Diagnostics welcomed the appointment but reiterated its opposition to Genetic Signatures’ proposed merger with Microba, saying the terms do not adequately reflect Genetic Signatures’ contribution and calling for more information and an independent assessment for its shareholders.

Updated 2026-10-28 16:10
Share
SourcesResults of 2026 EGM and Appointment of DirectorBDX: BCAL Welcomes Dr John Melki's Appointment to GSS Board
Comments